International Ophthalmology

, Volume 34, Issue 3, pp 661–665 | Cite as

Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation

  • Carlos Mateo
  • Micol AlkabesEmail author
  • Anniken Burés-Jelstrup
Case Report


OZURDEX® is a biodegradable drug delivery system which has been reported to be an effective treatment in cases of macular edema. However, migration of the implant into the anterior chamber with elevation of intraocular pressure and corneal decompensation might occur in some cases. We report a case of an 80-year-old male who underwent intravitreal scleral fixation of OZURDEX® due to postoperative macular edema secondary to complicated cataract surgery. He had a previous angle-supported lens implantation with superior Nd:YAG laser iridotomy. During surgery, the dexamethasone implant was introduced into the vitreous cavity and sutured to the sclera using a 10-0 non-absorbable polypropylene suture to prevent the risk of anterior complications in case of migration into the anterior chamber. After 6 months of follow-up, the macular edema had disappeared completely, the drug delivery system was not observed in the posterior segment and best-corrected visual acuity improved from 20/125 to 20/40 (Snellen equivalent). Neither anterior nor posterior segment complications were reported during the follow-up period. Intravitreal scleral fixation of the OZURDEX® to the pars plana could be recommended as an alternative technique to avoid anterior migration of the device in a patient with an anterior chamber intraocular lens, which may lead to corneal decompensation and increased intraocular pressure.


OZURDEX® Angle-supported intraocular lens Macular edema 

Supplementary material

Supplementary material 1 (MP4 33512 kb)


  1. 1.
    Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, Ozurdex® GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146PubMedCrossRefGoogle Scholar
  2. 2.
    Pardo-López D, Francés-Muñoz E, Gallego-Pinazo R, Díaz-Llopis M (2012) Anterior chamber migration of dexamethasone intravitreal implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol 250:1703–1704PubMedCrossRefGoogle Scholar
  3. 3.
    Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A (2012) Wandering Ozurdex® implant. J Ophthalmic Inflamm Infect 2:1–5PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Vela J, Crespí J, Andreu D (2012) Repositioning of dexamethasone intravitreal implant (Ozurdex®) migrated into the anterior chamber. Int Ophthalmol 32:583–584PubMedCrossRefGoogle Scholar
  5. 5.
    Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125:309–317PubMedCrossRefGoogle Scholar
  6. 6.
    Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group (2009) Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 147:1048–1054PubMedCrossRefGoogle Scholar
  7. 7.
    Herrero-Vanrell R, Cardillo JA, Kuppermann BD (2011) Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol 5:139–146PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Carlos Mateo
    • 1
  • Micol Alkabes
    • 1
    • 2
    Email author
  • Anniken Burés-Jelstrup
    • 1
  1. 1.IMO—Instituto de Microcirugía OcularBarcelonaSpain
  2. 2.Clinica Oculistica—Ospedale San GiuseppeMilanItaly

Personalised recommendations